Invest now
Biocon share price
Balanced risk
You have to be logged in to add this to Watchlist.- ₹420.80(-1.84%)August 13, 2026 11:12:29 AM IST
- NSE
- BSE
- Vol : 1.61 M (NSE + BSE)Last 20 day avg : 4.65 M
Biocon is trading -1.84% lower at Rs 420.80 as compared to its last closing price. Biocon has been trading in the price range of 424.60 & 417.30. There are 16 analysts who have initiated coverage on Biocon. There are 3 analysts who have given it a strong buy rating & 4 analysts have given it a buy rating. 3 analysts have given the stock a sell rating.The company posted a net profit of 141.10 Crores in its last quarter.Listed peers of Biocon include Sun Pharmaceutical Industries (0.31%), Divi's Laboratories (-1.41%), Torrent Pharmaceuticals (-0.41%).The Mutual Fund holding in Biocon was at 15.47% in 30 Jun 2026. The MF holding has decreased from the last quarter. The FII holding in Biocon was at 8.14% in 30 Jun 2026. The FII holding has decreased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Loading...
Key Metrics
Updated on 13 Aug 2026, 11:13 AM IST
- BetaMedium volatility0.89Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityHigher than industry0.45The debt-to-equity ratio, indicating a company's financial leverage.
- Dividend YieldLower than industry0.12Annual dividends as a percentage of the stock price.
- P/EHigher than historical values126.12Price-to-earnings ratio based on trailing 12-month earnings
- PEG RatioIndicates undervaluation-12.57The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
- P/B-The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
Price range
Day Range
|
| ||||
52 week range
|
| ||||
Biocon News
Biocon Peers
Return Comparison
Peers Comparison
Names | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | 1,941.00 | 0.31 | 4,65,699.95 | 38.40 | 5.55 | 0.83 | 0.47 |
| Divi's Laboratories | 8,424.50 | -1.41 | 2,23,644.00 | 73.32 | 11.48 | 0.41 | 0.03 |
| Torrent Pharmaceuticals | 4,870.00 | -0.41 | 1,85,232.52 | 72.73 | 19.22 | 0.80 | 141.16 |
| Cipla | 1,460.00 | -0.11 | 1,17,945.41 | 27.57 | 3.33 | 0.92 | 1.11 |
| Zydus Lifesciences | 1,172.00 | -2.66 | 1,16,907.45 | 21.19 | 4.24 | 0.09 | 14.22 |
Mutual Fund Ownership
View allBiocon Corporate Actions
View all- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2026-08-05 | Quarterly Results |
| 2026-05-07 | Audited Results & Final Dividend |
| 2026-02-12 | Quarterly Results |
| 2025-11-11 | Quarterly Results |
| 2025-10-01 | Redemption (Part) of NCD |
About the company Biocon
- IndustryBiotechnology & Drugs
- ISININE376G01013
- BSE Code532523
- NSE CodeBIOCON
Biocon Limited is an India-based biopharmaceutical company, engaged in the manufacture of biotechnology products and research services. The Company is in the business of manufacturing active pharmaceutical ingredients (APIs) and formulations, including biosimilar drugs for diabetics, oncology and autoimmune diseases. The Company’s segment includes Generics, Biosimilars, Novel Biologics and Research Services. It focuses on three key therapeutic areas - Oncology, Diabetes, and Immunology. Its APIs portfolio includes cardiovascular, anti-diabetics, immunosuppressants, and specialty molecules. Its products include Tacrolimus, Rosuvastatin, Simvastatin, Atorvastatin, Pravastatin, Fingolimod and others. Its APIs manufacturing facilities with capabilities in microbial fermentation, downstream process, including chromatographic purification, chemical synthesis, peptide synthesis and Highly Potent APIs (HPAPIs). It has over five facilities in Bangalore, Hyderabad and Visakhapatnam in India.
Biocon Share Price FAQs
Biocon is trading at 420.80 as on Thu Aug 13 2026 05:42:29. This is -1.84% lower as compared to its previous closing price of 428.70.
The market capitalization of Biocon is 68577.53 Cr as on Thu Aug 13 2026 05:42:29.
The average broker rating on Biocon is Hold. The breakup of analyst rating is given below -
- 3 analysts have given a strong buy rating
- 4 analysts have given a buy rating
- 3 analysts have given a hold rating
- 3 analysts have given a sell rating
- 3 analysts have given a strong sell rating
The 52 wk high for Biocon is 447.00 whereas the 52 wk low is 331.00
Biocon can be analyzed on the following key metrics -
- TTM P/E:
- Sector P/E: -
- Dividend Yield: %
- D/E ratio: -
Biocon reported a net profit of 385.60 Cr in 2026.
The Mutual Fund Shareholding was 15.47% at the end of 30 Jun 2026.
Quick Links
EQUITY QUICK LINKS
Biocon QUICK LINKS
FROM MARKETS
RELATED LINKS
Quarterly Results
✕
Wait for it…
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.